2216 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for genetic diseases Animal model for neurodegenerative disease, e.g. non- Alzheimer's
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME
#2AGENT FOR DETECTING STRUCTURALLY ABNORMAL PROTEIN AND AGENT FOR REDUCING STRUCTURALLY ABNORMAL PROTEIN
#3CONSTRUCTION METHOD AND USE OF Thy1-SNCA; Clu GENE KNOCKOUT MOUSE MODEL
#4OXR1 GENE THERAPY
#5ANIMAL MODEL OF TDP-43 PROTEINOPATHY
#6TRANSGENIC ANIMAL PHENOTYPING PLATFORM AND USES THEREOF
#7METHOD OF GENETIC MANIPULATION OF NEURAL CELLS IN GYRENCEPHALIC FETAL BRAIN AND USES THEREOF
#8Methods for Reducing Ataxin-2 Expression
#9METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES CAUSED BY A CNTNAP1 MUTATION
#10TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
#11COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING ALZHEIMER'S DISEASE
#12MODELS OF TAUOPATHY
#13NEURODEGENERATIVE AND AMYOTROPHIC MODEL ANIMAL
#14METHODS OF TREATING MITOCHONDRIAL DISORDERS
#15IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
#16MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY
#17IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
#18TREATMENT OF CANAVAN DISEASE
#19METHOD FOR DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY USING HPMA
#20TRPC3 AS A THERAPEUTIC TARGET FOR ALZHEIMER’S DISEASE
#21Models of tauopathy
#22TRANSGENIC ANIMAL PHENOTYPING PLATFORM AND USES THEREOF
#23ANIMAL MODEL, METHODS FOR MAKING AND USING THEREOF, AND COMPOSITION FOR TREATING ATAXIA
#24HUMANIZED CHIMERAS FOR THE PROSPECTIVE ASSESSMENT OF CELL ADDITION AND REPLACEMENT THERAPIES
#25MOTOR NEURON-SPECIFIC EXPRESSION VECTORS
#26METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
#27NON-HUMAN MAMMAL MODEL OF HUMAN DEGENERATIVE DISORDER, USES THEREOF, AND METHOD OF TREATING HUMAN DEGENERATIVE DISORDER
#28MONOGENIC OR POLYGENIC DISEASE MODEL ORGANISMS HUMANIZED WITH TWO OR MORE GENES
#29NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS COMPRISING A V30M MUTATION AND METHODS OF USE
#30METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
#31Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis (ALS) by UPF2
#32NON-HUMAN ANIMALS COMPRISING A HUMANIZED TRKB LOCUS
#33TRANSGENIC NON-HUMAN ANIMAL CAPABLE OF CONTROLLING EXPRESSION OF TRANSCRIPTION FACTOR RP58
#34COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR IDENTIFYING EFFICACIOUS AGENTS FOR TREATMENT OF THE SAME
#35GENE THERAPIES FOR LYSOSOMAL DISORDERS
#36Methods for reducing Ataxin-2 expression
#37OXR1 GENE THERAPY
#38Methods of treating mitochondrial disorders
#39PATIENT-DERIVED AMYLOID XENOGRAFT NON-HUMAN ANIMAL MODEL
#40NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTION
#41MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY
#42COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS
#43COMPOSITIONS AND METHODS FOR REGULATING MYELINATION
#44GENERATING GABAergic NEURONS IN BRAINS
#45THERAPEUTIC AGENT FOR FRONTOTEMPORAL LOBAR DEGENERATION, METHOD FOR SCREENING THERAPEUTIC AGENT FOR FRONTOTEMPORAL LOBAR DEGENERATION AND METHOD FOR TREATING FRONTOTEMPORAL LOBAR DEGENERATION
#46GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS TARGETING GANGLIOSIDE BIOSYNTHETIC PATHWAYS
#47Anti-Ryk antibodies and methods of using the same
#48MODELING TDP-43 PROTEINOPATHY
#49NON-HUMAN ANIMALS HAVING A HEXANUCLEOTIDE REPEAT EXPANSION IN A C9ORF72 LOCUS
#50Motor neuron-specific expression vectors
#51Methods for obtaining pluripotent adult olfactory stem cells from an olfactory mucosa tissue
#52EARLY-ONSET PARKINSON'S DISEASE MODEL: (D331Y) PLA2G6 KNOCKIN MODEL, PLATFORM AND METHOD FOR DRUG SCREENING, AND KIT OF DETECTION
#53Mouse with cholinergic neuron-specific inactivated ANO1 gene
#54TRPC3 as a therapeutic target for alzheimer's disease
#55Methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity by UPF1
#56INFORMATION PROVIDING METHOD FOR DIAGNOSING PARKINSONS DISEASE
#57Transgenic animal phenotyping platform and uses thereof
#58Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same
#59Transgenic mice with inducible neuron-specific inactivation of HuR gene and method of screening
#60Parkinson's disease model and methods
#61TDP-43 knock-in mouse model of amyotrophic lateral sclerosis
#62A NON-HUMAN ANIMAL MODEL OF NEURODEGENERATIVE DISORDERS
#63GENE FOR IDENTIFYING INDIVIDUALS WITH FAMILIAL DYSAUTONOMIA
#64NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTION
#65METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
#66Non-human animals having a disruption in a C9ORF72 locus
#67Alzheimer's disease animal model
#68Transgenic mice expressing human TREM proteins and methods of use thereof
#69Genetically modified rat comprising a humanized locus
#70Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
#71Anti-Ryk antibodies and methods of using the same
#72Methods of treating mitochondrial disorders
#73Methods and compositions for modulating gene expression
#74DNA molecules encoding antibodies to tau and methods of making thereof
#75Motor neuron-specific expression vectors
#76Combination therapies for treatment of spinal muscular atrophy
#77Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
#78Methods for treating a brain tissue damage by cultured adult pluripotent olfactory stem cells
#79Methods and compositions for modulating gene expression
#80Transgenic mouse model for dementia
#81Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locus
#82Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
#83Parkinsons disease model and methods
#84ANIMAL MODEL OF NEURONAL INJURY
#85COMPOSITIONS, METHODS AND USE OF SYNTHETIC LETHAL SCREENING
#86Generating GABAergic neurons in brains
#87Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#88Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#89Exon skipping technology in VCP disease
#90METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES AND AMYLOID BETA AMYLOIDOSIS BY MODULATING CRF RECEPTOR SIGNALING
#91COMPOSITIONS AND METHODS FOR MODULATING NEURONAL DEGENERATION
#92Tools and Methods for Targeting Oligonucleotide Repeat RNA Toxicity
#93VH4 ANTIBODIES AGAINST GRAY MATTER NEURON AND ASTROCYTE
#94Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
#95Non-human animals having a disruption in a C9ORF72 locus
#96Animal model and cell model developing amyotrophic lateral sclerosis
#97Metabolism-based drug screening platform in bioengineered zebrafish
#98Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#99Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
#100Alzheimer's disease animal model
#101Dosage compensating transgenes and cells
#102Animal Models of Ataxia-Telangiectasia (A-T)
#103Method for measuring cell-to-cell transmission of α-synuclein aggregates using bimolecular fluorescence complementation system and method for screening a substance for preventing or treating neurodegenerative disease using the same
#104Methods for diagnosis and treatment of amyotrophic lateral sclerosis based on an increased level of interaction between TDP-43 polypeptide and NF-KB P65 polypeptide
#105TRANSGENIC NON-HUMAN ORGANISMS WITH NON-FUNCTIONAL TSPO GENES
#106HUMAN-DERIVED MUTANTS OF THE dSOD1 GENE IN DROSOPHILA AND METHODS OF MAKING AND USING
#107Animal model of neuronal injury
#108Combination treatment for amyotrophic lateral sclerosis (ALS)
#109Methods of reducing TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis by a UPF1 polypeptide or polynucleotide
#110MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY
#111Animal model of Krabbe's disease
#112MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS AND/OR FRONTOTEMPORAL LOBAR DEGENERATION
#113TRANSGENIC MOUSE EXPRESSING HUMAN ISOGLUTAMINYL CYCLOTRANSFERASE
#114Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#115RbAp48 transgenic mice for drug discovery in age-related memory decline
#116Methods and compositions for preventing and treating a disease related to glycan dysregulation
#117Diagnosis marker, diagnosis method and therapeutic agent for amyotrophic lateral sclerosis, and animal model and cell model developing amyotrophic lateral sclerosis
#118Transgenic non-human animal model of neurodegenerative disease
#119Genetically engineered mouse model for autism spectrum disorder having deletion of gene and use thereof
#120Transgenic mouse having a genome comprising a homozygous disruption of the endogenous MFN2 gene expression in the dopaminergic neurons
#121hnRNP A1 KNOCKOUT ANIMAL MODEL AND USE THEREOF
#122Gene for Identifying Individuals with Familial Dysautonomia
#123CONDITIONAL EXPRESSION OF TRANSGENES IN VIVO
#124Assays of Neurodegenerative Disorders, including Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
#125METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION
#126DIAGNOSIS MARKER, DIAGNOSIS METHOD AND THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS, AND ANIMAL MODEL AND CELL MODEL DEVELOPING AMYOTROPHIC LATERAL SCLEROSIS
#127Sterol glucoside toxins
#128JNK3 MODULATORS AND METHODS OF USE
#129METHODS AND SYSTEMS FOR INDUCIBLE ABLATION OF NEURAL CELLS
#130METHOD FOR GENOME EDITING
#131TRANSGENIC ANIMAL MODEL OF NEURODEGENERATIVE DISORDERS
#132IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS
#133GENOMIC EDITING OF GENES INVOLVED WITH PARKINSONS DISEASE
#134Methods for testing for caloric restriction (CR) mimetics
#135ANIMAL MODEL FOR PARKINSON'S DISEASE
#136Non-human animal model for amyotrophic lateral sclerosis (ALS) with loss-of-TDP-43 function
#137Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#138Use of VEGF and homologues to treat neuron disorders
#139Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#140ASSAYS OF NEURODEGENERATIVE DISORDERS, INCLUDING FRONTOTEMPORAL DEMENTIA AND AMYOTROPHIC LATERAL SCLEROSIS
#141RAB3B for treatment and prevention of Parkinson's disease
#142Transgenic animal model of neurodegenerative disorders
#143MAO-B ELEVATION AS AN EARLY PARKINSON'S DISEASE BIOMARKER
#144Methods for introducing a human gene into a marmoset embryo for making a transgenic marmoset
#145TRANSGENIC MAMALS MODIFIELD IN BRI PROTEIN EXPRESSION
#146E-selectin compositions and use thereof for inducing E-selectin tolerance
#147HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCER
#148GENOMIC EDITING OF GENES INVOLVED IN AMYOTROPHYIC LATERAL SCLEROSIS DISEASE
#149GENOMIC EDITING OF NEURODEVELOPMENTAL GENES IN ANIMALS
#150GENOMIC EDITING OF GENES INVOLVED WITH PARKINSON'S DISEASE
#151Use of regulatory sequences for specific, transient expression in neuronal determined cells
#152Use of regulatory sequences for specific, transient expression in neuronal determined cells
#153GENOME EDITING OF SENSORY-RELATED GENES IN ANIMALS
#154GENOME EDITING OF GENES ASSOCIATED WITH TRINUCLEOTIDE REPEAT EXPANSION DISORDERS IN ANIMALS
#155Inhibitors of Caspase I-Dependent Cytokines in the Treatment of Neurodegenerative Disorders
#156METHOD OF IDENTIFYING COMPOUNDS THAT INDUCE OR INHIBIT ENDOPLASMIC RETICULUM STRESS OR OXIDATIVE STRESS
#157Transgenic Zebrafish Models for Neurodegenerative Diseases
#158Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
#159G-substrate for the treatment and prevention of parkinson's disease
#160TRANSGENIC ANIMAL MODELS OF PARKINSON'S DISEASE
#161Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
#162TRANSGENIC NON-HUMAN ANIMAL
#163Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
#164NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION
#165Use of VEGF and homologues to treat neuron disorders
#166Prion-free transgenic ungulates
#167SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES
#168Transgenic pig model for a hereditary neurodegenerative autosomal dominant disease
#169Mouse model and treatment of hereditary inclusion body myopathy
#170Parkinson's Disease-Related Gene GRK5 and Uses Thereof
#171Transgenic Zebrafish Models for Neurodegenerative Diseases
#172Gene for Identifying Individuals with Familial Dysautonomia
#173Use of regulatory sequences for specific, transient expression in neuronal determined cells
#174Non-invasive, in vivo fluorescent imaging of the nervous system in whole living animal
#175Methods and compositions for preventing and treating a disease related to glycan dysregulation
#176METHODS AND SYSTEMS FOR IDENTIFYING COMPOUNDS THAT MODULATE ALPHA-SYNUCLEIN AGGREGATION
#177TRANSGENIC ORGANISM
#178Semaphorin Gene Family
#179Transgenic animal model of neurodegenerative disorders
#180Soluble Hybrid Prion Proteins And Their Use In The Diagnosis, Prevention And Treatment Of Transmissible Spongiform Encephalopathies
#181Inducing neurofibrillary tangles in transgenic mice expressing a mutant tau protein
#182Treatment and prevention of vascular dementia
#183Growth Differentiation Factor-8
#184Methods and compositions to treat misfolded-SOD1 mediated diseases
#185IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS
#186Vector system
#187Transgenic Animal Models for Neurodevelopmental Disorders
#188Methods of using BCL-2 for the therapeutic treatment and prevention of diseases
#189Transgenic mice for screening for inhibitors of protein aggregation and methods for making and using them
#190MODEL FOR NEURODEGENERATIVE DISEASES INVOLVING AMYLOID ACCUMULATION
#191Use of VEGF and homologuest to treat neuron disorders
#192Method of proliferation in neurogenic regions
#193Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
#194Use of VEGF and homologues to treat neuron disorders
#195Methods for testing for caloric restriction (CR) mimetics
#196Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
#197Vertebrate embryonic pattern-inducing proteins, and uses related thereto
#198Regulators of protein misfolding and aggregation and methods of using the same
#199Monitoring APP cleavage in transgenic rodents comprising an APP Swedish mutation
#200Transgenic non-human mammal
#201Transgenic mice containing TRP gene disruptions
#202HUMAN DISEASE MODELING USING SOMATIC GENE TRANSFER
#203Methods and means for treating protein conformational disorders
#204Use of regulatory sequences for specific, transient expression in neuronal determined cells
#205Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
#206Transgenic rat as animal model for human huntingdon's disease
#207Semaphorin gene family
#208Nonhuman model animal suffering from Guillain-Barré syndrome and/or fisher syndrome
#209Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
#210Diagnostic and therapeutic use of a rab family gtp-binding protein for neurodegenerative diseases
#211Methods for treating demyelination disorders
#212Sterol glucoside toxins
#213Non-naturally occurring animal that expresses an untranslated non-coding RNA
#214Methods and compositions for screening for modulators of neuronal cell death in Parkinson's disease
#215Methods for the identification of compounds for the treatment of Alzheimer's disease
#216Methods and compositions for screening for modulators of Parkinson's disease
#217Treatment of neurodegenerative conditions with nimesulide
#218Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
#219JNK3 modulators and methods of use
#220Compositions and methods for producing and using homogenous neuronal cell transplants
#221Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
#222Prion-free transgenic ungulates
#223Methods for detecting mutations associated with familial dysautonomia
#224Knockin non-human animal and tissue-specific MnSOD knockout non-human animal
#225Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells
#226Models of prion disease
#227Mouse showing neurofibril change due to senile dementia
#228Monitoring APP cleavage in transgenic rodents comprising an APP-Swedish mutation
#229Screening methods employing fish model assessment of vision
#230Method of inducing the formation of neurofibrillary tangles in transgenic animals
#231Transgenic mice expressing inducible human p25
#232Vertebrate embryonic pattern-inducing proteins and uses related thereto
#233Method of screening for compounds that modulate activity of a regulatory sequence of the β-2 subunit of a neuronal nicotinic acetylcholine receptor